Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin type A for treating voice tremor.

Charles H Adler1, Stephen F Bansberg, Joseph G Hentz

  • 1Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA. cadler@mayo.edu

Archives of Neurology
|September 15, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy.

JAMA network open·2026
Same author

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
Same author

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same author

Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Dose-dependent white matter changes associated with repetitive head impacts in former American football players.

Brain communications·2026
Same author

Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts.

Alzheimer's research & therapy·2026

Botulinum toxin type A injections effectively treat voice tremor, improving severity and function with minimal side effects like breathiness and dysphagia. This study confirms its efficacy for patients with voice tremor.

Area of Science:

  • Neurology
  • Otolaryngology
  • Pharmacology

Background:

  • Voice tremor, similar to spasmodic dysphonia, can be managed with botulinum toxin type A.
  • Botulinum toxin type A is a potential therapeutic agent for tremor disorders.

Purpose of the Study:

  • To assess the safety and effectiveness of botulinum toxin type A injections for treating voice tremor.
  • To determine optimal dosage and patient response to botulinum toxin type A therapy.

Main Methods:

  • A randomized, single-site study involving 13 subjects with voice tremor.
  • Patients received varying doses of botulinum toxin type A (1.25 U, 2.5 U, or 3.75 U) bilaterally in the vocal cords.
  • Evaluations included patient tremor rating scales, functional disability, and acoustic measures over a 6-week follow-up period.

Related Experiment Videos

Main Results:

  • All participants experienced a positive effect from botulinum toxin type A injections, with symptom onset within 1-7 days.
  • Significant improvements were observed in patient-rated tremor severity, functional disability, and acoustic measures.
  • Common adverse effects included breathiness and dysphagia across all dosage groups.

Conclusions:

  • Botulinum toxin type A injections are a safe and effective treatment for voice tremor.
  • The study supports the use of botulinum toxin type A for improving voice tremor symptoms and quality of life.